Results 121 to 130 of about 3,490 (164)
Some of the next articles are maybe not open access.
Impurity profile study of dutasteride
Die Pharmazie, 2007During the process development of dutasteride in the laboratory analysis showed some impurity peaks in HPLC ranging from 0.05 to 0.1%. The same samples were analyzed by LCMS method and identified peak at m/z 508 (desmethyl dutasteride), 530 (dihydro dutasteride) and 528 (isomer of dutasteride).
K, Satyanarayana +3 more
openaire +2 more sources
Drugs, 2008
Dutasteride (Avodart), an oral synthetic 4-azasteroid, is a potent, selective, irreversible inhibitor of type 1 and type 2 5alpha-reductase (5AR), the enzyme that converts testosterone to dihydrotestosterone (DHT) intracellularly. Although type 2 5AR predominates, both isoenzymes are overexpressed in prostate tissue in benign prostatic hyperplasia (BPH)
Susan J, Keam, Lesley J, Scott
openaire +2 more sources
Dutasteride (Avodart), an oral synthetic 4-azasteroid, is a potent, selective, irreversible inhibitor of type 1 and type 2 5alpha-reductase (5AR), the enzyme that converts testosterone to dihydrotestosterone (DHT) intracellularly. Although type 2 5AR predominates, both isoenzymes are overexpressed in prostate tissue in benign prostatic hyperplasia (BPH)
Susan J, Keam, Lesley J, Scott
openaire +2 more sources
Drugs & Aging, 2012
The 5α-reductase inhibitor dutasteride and the α(1)-adrenergic receptor antagonist tamsulosin are available as a fixed-dose combination for use in men with symptomatic benign prostatic hyperplasia (BPH) and an enlarged prostate. Dutasteride 0.5 mg/day plus tamsulosin 0.4 mg/day improved lower urinary tract symptoms (LUTS) to a significantly greater ...
openaire +2 more sources
The 5α-reductase inhibitor dutasteride and the α(1)-adrenergic receptor antagonist tamsulosin are available as a fixed-dose combination for use in men with symptomatic benign prostatic hyperplasia (BPH) and an enlarged prostate. Dutasteride 0.5 mg/day plus tamsulosin 0.4 mg/day improved lower urinary tract symptoms (LUTS) to a significantly greater ...
openaire +2 more sources
Dutasteride and Prostate Cancer Risk
Current Urology Reports, 2010In a previously published and heavily discussed paper [1], the type 2 5-α-reductase inhibitor (5ARI) finasteride was shown to reduce the risk of prostate cancer by a substantial 25% as compared to placebo in men at no known risk of developing prostate cancer.
openaire +2 more sources